ANTIMICROBIAL CHEMOTHERAPY IN CYSTIC FIBROSIS PATIENTS

Acta Pædiatrica

Volumn 71, Issue , 1982, Pages 75-100

  HØIBY, NIELS ^a   FRIIS, BIRGITTE ^a   JENSEN, KLAUS ^a   KOCH, CHRISTIAN ^a   MØLLER, NIELS ERIK ^a   STØVRING, SØREN ^a   SZAFF, MARTHA ^a  

^a Rigshospitalet   (Denmark)

Author keywords

antimicrobial chemotherapy; Cystic fibrosis; Haemophilus influenzae; Pseudomonas aeruginosa; Staphylococcus aureus; Streptococcus pneumoniae

Indexed keywords

AMIKACIN; AMOXICILLIN; ANTIBIOTIC AGENT; AZLOCILLIN; CARBENICILLIN; CEFOTAXIME; CEFSULODIN; CEFTAZIDIME; COLISTIN; COTRIMOXAZOLE; DICLOXACILLIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LATAMOXEF; METICILLIN; NEOMYCIN; NETILMICIN; PENICILLIN V; PIPERACILLIN; PIVAMPICILLIN; RIFAMPICIN; TOBRAMYCIN;

CHEMOTHERAPY; CYSTIC FIBROSIS; DRUG SENSITIVITY; DRUG THERAPY; HAEMOPHILUS INFLUENZAE; HUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THERAPY;

EID: 0020445363     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.1982.tb09643.x     Document Type: Article

References (132)

1. A therapeutic regimen for patients with cystic fibrosis
2. Therapy and prognosis of fibrocystic diseases of the pancreas
3. Cystic fibrosis of the pancreas
4. Research in cystic fibrosis
5. Cystic fibrosis
6. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis
7. Mucus secretion and clearance in the pathogenesis of cystic fibrosis
8. Summary of a workshop on infections in patients with cystic fibrosis
9. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis
10. Antibiotic management of cystic fibrosis
11. Cystisk fibrose
12. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients
13. The immediate effect of physiotherapy and aerosol treatment on pulmonary function in children with cystic fibrosis
14. Short‐term effects of chest physiotherapy on pulmonary function in children with cystic fibrosis
15. Acute pulmonary exacerbations in cystic fibrosis. A double‐blind trial of tobramycin and placebo therapy
16. The prognosis in cystic fibrosis in Denmark in 1945–1974
17. In vivo penetration of antibiotics into sputum in cystic fibrosis
18. Effects of sputum from patients with cystic fibrosis on the activity in vitro of 5 antimicrobial drugs on Pseudomonas aeruginosa
19. Interaction of purulent material with antibiotics used to treat Pseudomonas infections
20. Concentration of gentamicin in bronchial secretions of children with cystic fibrosis or tracheostomy
21. A simple screening test for beta‐lactamase activity in sputum
22. Evaluation of a high dose tobramycin and ticarcillin treatment protocol in cystic fibrosis based on improved susceptibility criteria and antibiotic pharmocokinetics
23. The carbenicillin‐potentiating effect of N‐acetylcysteine in vitro
24. Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease
25. Outpatient intravenous medications in the management of cystic fibrosis
26. Safety of long duration intravenous heparinlock needles for administration of antibiotics to cystic fibrosis patients
27. Antibiotic therapy of Pseudomonas infection in patients with cystic fibrosis
28. Staphycococcus aureus in cystic fibrosis: Antibiotic sensitivity and phage types during the latest decade. Investigations of the occurrence of protein A and some other properties of recently isolated strains in relation to the occurrence of precipitating antibodies
29. Isolation of Staphylococcus aureus from sputum in cystic fibrosis
30. Persistence of thymine‐dependent Staphylococci in C.F. sputum: a pitfall for the unwary
31. Development of Pseudomonas aeruginosa strains resistant to carbenicillin, azlocillin, piperacillin and tobramycin during chemotherapy in cystic fibrosis patients
32. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis
33. Pseudomonas colonization in cystic fibrosis. A study of 160 patients
34. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis
35. Tetracycline discoloration, enamel defects, and dental caries in patients with cystic fibrosis
36. Optic neuritis as a complication to treatment of cystic fibrosis with chloramphenicol
37. Are measurements of urine enzymes useful during aminoglycoside therapy
38. Aerosol therapy in cystic fibrosis
39. Side‐effects of carbenicillin treatment in patients with cystic fibrosis with chronic infections with Pseudomonas aeruginosa
40. Allergological examination of cystic fibrosis patients with skin reactions during carbenicillin treatment
41. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin
42. Pharmacokinetics of netilmicin in children with and without cystic fibrosis
43. Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis
44. Pharmacokinetics of azlocillin in children with cystic fibrosis
45. Pharmacokinetics of tobramycin in cystic fibrosis
46. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis
47. Pharmacokinetics of methicillin in patients with cystic fibrosis
48. Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluation
49. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis
50. Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis
51. Tobramycin treatment of Pseudomonas aeruginosa infections in cystic fibrosis
52. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis
53. Pulmonary deposition of aerosol in children with cystic fibrosis
54. Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis
55. The management of cystic fibrosis. Observations on gentamicin when used with other antibiotics in pulmonary infections associated with cystic fibrosis
56. Effect of subminimum inhibitory concentrations of antibiotics on Pseudomonas aeruginosa; the MIC/MAC ratio
57. Activities of new betalactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis
58. Antipseudomonal β‐lactams
59. Recent advances in the therapy of Pseudomonas aeruginosa infection
60. Antibiotics and Pseudomonas aeruginosa
61. Serotypes and antibiotic susceptibilities of Pseudomonas aeruginosa isolates from single sputa of cystic fibrosis patients
62. Heterogeneity of antibiotic resistance in mucoid isolates of Pseudomonas aeruginosa obtained from cystic fibrosis patients: role of outer membrane proteins
63. Epidemiology of Pseudomonas aeruginosa infection in patients treated at a cystic fibrosis centre
64. Bacteriophages in sputum of patients with bronchopulmonary Pseudomonas infections
65. Transduction of amikacin, gentamicin and tobramycin. Resistance in Pseudomonas aeruginosa with phage F 116 and AP 19, a new wildtype phage
66. Antibiotic therapy and cystic fibrosis: increased resistance of mucoid Pseudomonas aeruginosa to carbenicillin
67. Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid form to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro
68. The penetration of antibiotics through sodium alginate and through the exopolysaccharide of a mucoid strain of Pseudomonas aeruginosa
69. Sensitivity of respiratory strains of Pseudomonas aeruginosa to carbenicillin
70. Susceptibility of mucoid Pseudomonas aeruginosa to gentamicin disks
71. Effect of antibiotics on mucoid strains of Pseudomonas aeruginosa
72. Effect of mucoid property on antibiotic susceptibility of Pseudomonas aeruginosa
73. Antimicrobial susceptibility of mucoid Pseudomonas aeruginosa and their spontaneously occurring non‐mucoid derivatives
74. Resistance to antimicrobial agents: the general nature of the problem and the basis of resistance
75. Mechanisms of resistance to aminoglycosides in clinical isolates
76. Aminoglycoside uptake and mode of action –‐ with special reference to streptomycin and gentamicin
77. Characterization of cefsulodin‐resistant variants of Pseudomonas aeruginosa
78. Resistance of Pseudomonas aeruginosa to antibiotics
79. Cephalosporinase and penicillinase activities of a β‐lactamase from Pseudomonas pyocyanea
80. Penetration of β‐lactam antibiotics into their target enzymes in Pseudomonas aeruginosa: Comparison of a highly sensitive mutant with its parent strain
81. Penicillin‐binding proteins of Pseudomonas aeruginosa. Comparison of two strains differing in their resistance to β‐lactam antibiotics
82. Competition of β‐lactam antibiotics for the penicillin‐binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes, Proteus rettgeri, and Escherichia coli: Comparison with antibacterial activity and effects upon bacterial morphology
83. Outer membrane permeability in Pseudomonas aeruginosa: Comparison of a wild‐type with an antibiotic‐supersusceptible mutant
84. Chemical and chromatographic analysis of lipopolysaccharide from an antibiotic‐supersusceptible mutant of Pseudomonas aeruginosa
85. Limited contribution of the outer‐membrane penetration barrier towards intrinsic antibiotic resistance in Pseudomonas aeruginosa
86. Modified peptidoglycan transpeptidase activity in a carbenicillin‐resistant mutant of Pseudomonas aeruginosa 18s
87. Mutation of Pseudomonas aeruginosa specifying reduced affinity for penicillin G
88. β‐lactam‐resistant Pseudomonas aeruginosa with modified penicillin‐binding proteins emerging during cystic fibrosis treatment
89. Pseudomonas aeruginosa in nature and disease
90. Regrowth of Pseudomonas aeruginosa and other bacteria after the bactericidal action of carbenicillin and other β‐lactam antibiotics
91. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin
92. Is anti‐Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis
93. A double‐blind controlled trial of anti‐Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis
94. Pseudomonas aeruginosa pulmonary infections (emphasizing nosocomial pneumonia and respiratory infections in cystic fibrosis)
95. Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis
96. Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis
97. The treatment of exacerbations of pulmonary disease in cystic fibrosis: Netilmicin compared with netilmicin and carbenicillin
98. Tobramycin therapy of pulmonary infections in patients with cystic fibrosis
99. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis
100. Cures intensive d'antibiotiques dans les mucoviscidoses évoluées
101. Azlocillin compared with carbenicillin, and tobramycin compared with gentamicin in the treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis
102. Antibiotic inhibition of protease production by Pseudomonas aeruginosa
103. Treatment of pulmonary Pseudomonas aeruginosa infection in cystic fibrosis with cefsulodin combined with tobramycin. In: Proceedings of the 12th international congress of chemotherapy
104. Tuberculosis treated with rifampicin, ethambutol and isoniazid